摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

erythro-(+/-)-(E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester | 129332-29-2

中文名称
——
中文别名
——
英文名称
erythro-(+/-)-(E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester
英文别名
t-butyl (E)-3,5-dihydroxy-7-[3'-(4''-fluorophenyl)-1'-methylethyl-indol-2'-yl]hept-6-enoate;(+/-)-erythro-(E)-7-[3-(4-fluoro-phenyl)-1-(1-methyl-ethyl)-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid t-butyl ester;t-Butyl(E)-3,5-dihydroxy-7-[3'-(4''-fluorophenyl)-1'-methylethyl-indol-2'-yl]-6-heptenoate;tert-butyl (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoate
erythro-(+/-)-(E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester化学式
CAS
129332-29-2
化学式
C28H34FNO4
mdl
——
分子量
467.581
InChiKey
USGKHYXJISAYPE-CCEZHUSRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    138-143oC
  • 沸点:
    642.3±55.0 °C(Predicted)
  • 密度:
    1.13±0.1 g/cm3(Predicted)
  • 溶解度:
    氯仿(微溶)、乙酸乙酯(微溶)
  • LogP:
    3.3-5.3 at 23℃

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    34
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    71.7
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2933997500
  • WGK Germany:
    3

SDS

SDS:cfafe20b5ca75bc6f649eec8796460a1
查看

反应信息

点击查看最新优质反应信息

文献信息

  • PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF
    申请人:Koftis Theoharis V.
    公开号:US20120035374A1
    公开(公告)日:2012-02-09
    The present invention relates to an improved process for the preparation of fluvastatin or pharmaceutical acceptable salts or derivatives thereof, in particular to a one-pot process for large scale production of Fluvastatin and salts thereof in high yield and high purity and pharmaceutical preparations containing said compounds.
    本发明涉及一种改进的制备fluvastatin或其药学上可接受的盐或衍生物的工艺,特别是一种一锅法大规模生产高产量和高纯度fluvastatin及其盐的工艺和含有该化合物的制药制剂。
  • Process for the preparation of indole derivatives
    申请人:Wolleb Heinz
    公开号:US20050032875A1
    公开(公告)日:2005-02-10
    A process for the preparation of compounds of formula (I) wherein R 1 is unsubstituted or substituted C 1 -C 8 alkyl, R 2 , R 3 , R 4 and R 5 are each independently of the others hydrogen, unsubstituted or substituted C 1 -C 8 alkyl, C 1 -C 8 alkoxy, phenoxy or benzyloxy, or halogen, Y 1 and Y 2 are each independently of the other hydrogen or a protecting group, or Y 1 and Y 2 together form a protecting bridge, and X 1 is hydrogen, an organic radical or a cation, in which process a compound of formula (II) wherein R 1 R 2 , R 3 , R 4 and R 5 are as defined above and Z 1 is a leaving group, is reacted, in the presence of a catalytically effective amount of a palladium catalyst, with a compound of formula (III) wherein R 6 is hydrogen, bromine, chlorine, iodine, —OSO 2 CF 3 , —COCI, —B(OH) 2 or a mono- or di-ester derived from —B(OH) 2 , Y 3 and Y 4 are each a protecting group, or Y 3 and Y 4 together form a protecting bridge, and X 1 is as defined above, to form a compound of formula (IV) and if desired the radicals Y 3 and Y 4 are converted into the radicals Y 1 and Y 2 where Y 1 and Y 2 are hydrogen.
    一种制备式为(I)化合物的方法,其中R1是未取代或取代的C1-C8烷基,R2、R3、R4和R5各自独立地为氢、未取代或取代的C1-C8烷基、C1-C8烷氧基、苯氧基或苄氧基,或卤素,Y1和Y2各自独立地为氢或保护基,或Y1和Y2共同形成保护桥,X1为氢、有机基团或阳离子,在该方法中,式为(II)的化合物与式为(III)的化合物反应,其中R1、R2、R3、R4、R5和X1如上所定义,Z1为离去基团,存在催化作用的钯催化剂的情况下,其中R6为氢、溴、氯、碘、-OSO2CF3、-COCI、-B(OH)2或由-B(OH)2衍生的单酯或双酯,Y3和Y4各自为保护基,或Y3和Y4共同形成保护桥,X1如上所定义,形成式为(IV)的化合物,如果需要,将基团Y3和Y4转化为基团Y1和Y2,其中Y1和Y2为氢。
  • PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES AND INTERMEDIATES OF THE PROCESS
    申请人:Ciba Specialty Chemicals Holding Inc.
    公开号:EP1284964A1
    公开(公告)日:2003-02-26
  • PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES
    申请人:Ciba Speciality Chemicals Holding Inc.
    公开号:EP1423365A1
    公开(公告)日:2004-06-02
  • IMPROVED PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF
    申请人:Pharmathen S.A.
    公开号:EP2419407B1
    公开(公告)日:2012-11-14
查看更多